OFF-X (Translational Safety/Toxicology), and its Cortellis Drug Discovery Intelligence with BioMarkers Module software application license subscription

This Special Notice from the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse announces intent to award a sole source contract to Clarivate Analytics LLC for a software subscription and user license to the OFF-X (Translational Safety/Toxicology) and Cortellis Drug Discovery Intelligence software application with BioMarkers Module. The National Institute on Drug Abuse seeks to renew its user license and subscription to the software it has used since 2014 to identify pharmaceutical companies interested in investing in SBIR/STTR companies and promising drugs not currently used in substance abuse research.

The Notice seeks to renew the Institute's user license and subscription to the OFF-X and Cortellis software application in order to continue identifying pharmaceutical companies interested in SBIR/STTR investments and promising compounds for substance abuse research. Interested parties have until March 25, 2024 to submit a response demonstrating their capability to provide a comparable drug development database and system, including pricing, terms, and business certifications. Only parties able to provide a comprehensive drug development database and identification system will be considered as an alternative to the sole source award to Clarivate Analytics.